PURPOSE: A delayed release formulation containing duloxetine or a pharmaceutically acceptable salt thereof is provided to prevent interaction of duloxetine and an enteric coating film and to ensure stable release.CONSTITUTION: A delayed release formulation comprises: a drug layer containing duloextine or a pharmaceutically acceptable salt thereof and a binder of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, or polyvinyl pyrrolidone and an enteric coating layer which is directly formed on the drug layer. The enteric coating layer contains an enteric coating base of hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, or a methacrylic acid copolymer.COPYRIGHT KIPO 2013[Reference numerals] (AA) Embodiment 9. Elution test under an accelerating condition (BB) Elution rate(%) (CC) Time(minutes) (DD) 15 days (EE) 30 days (FF) 45 days (GG) 60 days본 발명은 둘록세틴 또는 이의 약학적으로 허용되는 염을 포함하는 지연 방출형 제제에 관한 것이다. 보다 구체적으로, 본 발명은 둘록세틴 또는 이의 약학적으로 허용되는 염 및 특정 결합제를 함유하는 약물층 및 장용성 코팅층을 포함하는 지연 방출형 정제 및 이의 제조방법에 관한 것이다.
